Information Provided By: 
Fly News Breaks for April 18, 2018
SUPN
Apr 18, 2018 | 08:31 EDT
After hosting investor meetings with management, Jefferies analyst David Steinberg believes Supernus Pharmaceuticals looks on track to exceed guidance for the year. Supernus will likely buy an asset this year, with a focus likely on a pipeline candidates versus drug on the market, Steinberg tells investors in a research note. He notes the company has a $640M war chest. The analyst keeps a Buy rating on the shares with a $54 price target.
News For SUPN From the Last 2 Days
There are no results for your query SUPN
